Arrowhead Research reported $-173.08M in Stock for its fiscal quarter ending in December of 2024.





Stock Change Date
Agios Pharmaceuticals USD 37.84M 2.09M Sep/2026
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
Anika Therapeutics USD 28.56M 5.73M Jun/2026
Arrowhead Research USD -173.08M 173.08M Dec/2024
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Incyte USD 134.25M 21.71M Sep/2026
Ionis Pharmaceuticals USD 28.58M 22.26M Sep/2026
Ligand Pharmaceuticals USD 14.51M 4.24M Sep/2026
Merck USD 6.16B 43M Sep/2026
Moderna USD 313M 33M Sep/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Novartis USD 6.1B 116M Sep/2026
Sarepta Therapeutics USD 876.12M 28.15M Sep/2026
TG Therapeutics USD 194.32M 46.35M Sep/2026
Ultragenyx Pharmaceutical USD 59M 0 Sep/2026
Vertex Pharmaceuticals USD 2.25B 480.2M Sep/2026